Age-related macular degeneration and resource utilization in the Brazilian public healthcare system: a real-world retrospective study

• Published in: BMC ophthalmology Vol. 21; no. 1; p. 430
• Main Authors: Touma-Falci, Liane, Moreira-Neto, Carlos Augusto, Taleb, Alexandre Chater, Prieto, Marcela Bach, Packer, Thais, Oliveira, Julio Cesar Barbour, Birck, Marina Gabriela, Julian, Guilherme Silva, Forestiero, Francisco Jose
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.12.2021; BioMed Central; BMC
• Subjects: Adolescent; Adult; Age; Age-related macular degeneration; Aged; Angiogenesis Inhibitors - therapeutic use; Antiangiogenic treatment; Blindness; Care and treatment; Codes; Data analysis; Datasus; Delivery of Health Care; Female; Health care; Hospitalization; Humans; Information systems; Macular degeneration; Macular Degeneration - diagnosis; Macular Degeneration - drug therapy; Macular Degeneration - epidemiology; Male; Medical care; Medical care, Cost of; Medical treatment; Ophthalmology; Patients; Physiological aspects; Population; Public health; Public health system; Real world data; Reimbursement; Resource utilization; Retina; Retrospective Studies; Tomography; Tomography, Optical Coherence; Utilization; Brazil; Datasus; Real world data; Public health system; Age-related macular degeneration; Antiangiogenic treatment
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/s12886-021-02181-1

Age-related macular degeneration (AMD) is a disease that causes damage in the macular region of the retina, leading to irreversible blindness. This study aims to understand the profile and care of patients with AMD and its cost at the Brazilian public health system to identify AMD-care needs. This is a retrospective observational study of AMD with real-world data from the Brazilian public healthcare system, using DATASUS claim databases. Patients with AMD were selected from 01/Jan/2014 to 31/Jan/2020; had at least one claim of ICD10 code H35.3 (Degeneration of macula and posterior pole), and were submitted to one of two procedures exclusively available for AMD patients - optical coherence tomography (OCT) and medical treatment of retinal disease (antiangiogenic); aged ≥18 years at first ICD10 claim, and presenting at least 1 year of follow-up in the database. We described patients' characteristics, healthcare resource utilization and cost, and the antiangiogenic intravitreal treatment received by AMD patients, including the number of doses and interval time between them. Patients searching for AMD treatment since 2014 were mostly females (59%), white (61%), and a mean age of 72 years. They were mainly located in the Southeast (87%), and few patients were found in the North (1%) and Central-West (1.5%) regions, probably reflecting where the Brazilian guideline to treat AMD (Protocolo Clínico e Diretrizes Terapêuticas - PCDT) was incorporated as routine care for AMD. The average antiangiogenic dose of 2.5 antiangiogenic therapies within a year was below the expected. Most injections had an interval time of 20 to 40 days between doses, although some patients were treated more than 100 days. Another setback is that patients traveled longer distances for OCT and antiangiogenic treatment than overall AMD-healthcare, between 10 and 100 km. AMD patients seem to be undertreated, as they receive a mean of 2.5 doses of antiangiogenic treatment within a year. Inequalities among regions are evident, as the Southeast and South regions comprise almost all patients receiving the treatment from the public health system, probably reflecting the region with more access to AMD care according to PCDT recommendations.